Cargando…
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Nature Singapore
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399229/ https://www.ncbi.nlm.nih.gov/pubmed/35999219 http://dx.doi.org/10.1038/s41421-022-00425-y |
| _version_ | 1784772476676341760 |
|---|---|
| author | Ma, Xuhui Wu, Shanshan Li, Botai Zhang, Qianqian Zhang, Jianming Liu, Wenming Yan, Hexin Bernards, René Qin, Wenxin Wang, Cun |
| author_facet | Ma, Xuhui Wu, Shanshan Li, Botai Zhang, Qianqian Zhang, Jianming Liu, Wenming Yan, Hexin Bernards, René Qin, Wenxin Wang, Cun |
| author_sort | Ma, Xuhui |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9399229 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Springer Nature Singapore |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93992292022-08-25 EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma Ma, Xuhui Wu, Shanshan Li, Botai Zhang, Qianqian Zhang, Jianming Liu, Wenming Yan, Hexin Bernards, René Qin, Wenxin Wang, Cun Cell Discov Correspondence Springer Nature Singapore 2022-08-23 /pmc/articles/PMC9399229/ /pubmed/35999219 http://dx.doi.org/10.1038/s41421-022-00425-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Ma, Xuhui Wu, Shanshan Li, Botai Zhang, Qianqian Zhang, Jianming Liu, Wenming Yan, Hexin Bernards, René Qin, Wenxin Wang, Cun EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title_full | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title_fullStr | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title_full_unstemmed | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title_short | EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| title_sort | egfr blockade confers sensitivity to cabozantinib in hepatocellular carcinoma |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399229/ https://www.ncbi.nlm.nih.gov/pubmed/35999219 http://dx.doi.org/10.1038/s41421-022-00425-y |
| work_keys_str_mv | AT maxuhui egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT wushanshan egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT libotai egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT zhangqianqian egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT zhangjianming egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT liuwenming egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT yanhexin egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT bernardsrene egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT qinwenxin egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma AT wangcun egfrblockadeconferssensitivitytocabozantinibinhepatocellularcarcinoma |